Therapeutic effect of TRC105 and decitabine combination in AML xenografts

Acute myeloid leukemia (AML) is an aggressive hematologic malignancy, often characterized by poor prognosis following standard induction therapy. The hypomethylating agent decitabine (DAC) is an alternative treatment for elderly and relapsed/refractory AML patients, yet responses following DAC monot...

Descripción completa

Detalles Bibliográficos
Autores principales: Baik, June, Felices, Martin, Yingst, Ashley, Theuer, Charles P., Verneris, Michael R., Miller, Jeffrey S., Perlingeiro, Rita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566100/
https://www.ncbi.nlm.nih.gov/pubmed/33088975
http://dx.doi.org/10.1016/j.heliyon.2020.e05242

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566100/
https://www.ncbi.nlm.nih.gov/pubmed/33088975
http://dx.doi.org/10.1016/j.heliyon.2020.e05242

Ejemplares similares